Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of severe aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation which transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia.…
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Anteris Technologies Global (NASDAQ: AVR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 174 employees.
The shares were at 4.990 USD on 20 November 2026, up 46.8% over 52 weeks. Its 52-week range is 3.300 USD to 11.05 USD: the price is 54.9% below the high and 51.2% above the low.
Its market capitalisation is 486.49M USD.
Anteris Technologies Global reports revenue up 21.0% year over year.
It holds more cash than debt, a net cash position of 216.18M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.75 USD is 175.6% above the current price. The next earnings report is expected on 25 February 2027.